Brean Capital downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Buy to Hold.

Analyst Jonathan Aschoff said, "Today, Ariad announced updated ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE